Relief Therapeutics Holding AG (RLFTF)

[changes_iv]

Respiratory diseases are leading causes of death and disability in the world. About 65 million people suffer from chronic obstructive pulmonary disease (COPD) and 3 million die from it each year, making it the third leading cause of death worldwide. https://www.who.int/gard/publications/The_Global_Impact_of_Respiratory_Disease.pdf

Besides the disease burden, COPD is also associated with substantial economic costs. In the European Union, the total direct costs for COPD are estimated to be about 3% (€38.6 billion) of the total health care budget
https://respiratory-research.biomedcentral.com/articles/10.1186/s12931-019-1179-7

Cigarette smoke is an important risk factor for COPD and it is known to adversely affect surfactant. In a series of 20 smoker, non-asthmatic COPD patients compared with 5 nonsmoker healthy controls we found a marked decrease (about 6-7 times) of total phospholipids in bronchoalveolar lavage fluids.

https://www.karger.com/Article/PDF/196100
Think that RLF-100 will help alleviate this condition?